Immunological and immunohistochemical analysis of rheumatoid nodules

NOBUYUKI MIYASAKA,1 KAZUTO SATO,1 KAZUHIKO YAMAMOTO,2 MAKOTO GOTO,3 AND KUSUKI NISHIOKA1

From the 1Division of Clinical Immunology, Institute of Rheumatology, Tokyo Women’s Medical College, Tokyo, Japan; the 2Department of Medicine and Physical Therapy, Faculty of Medicine, Tokyo University; and the 3Division of Rheumatology, Tokyo Metropolitan Otsuka Hospital, Japan

SUMMARY An attempt was made to examine the pathophysiology of the rheumatoid nodule. Significant amounts of interleukin 1-like activity and prostaglandin E2 were detected in the supernatants from in vitro organ cultures of rheumatoid nodule tissue. When fresh (but not old) rheumatoid nodules were minced and cultured in vitro prominent outgrowths of cells were observed. These cells expressed both HLA-DR and CD14 antigens but lacked conventional differentiation antigens for T cells and B cells, suggesting that they are of monocyte-macrophage origin. These data suggest that interleukin 1 and prostaglandin E2 may be deeply involved in the formation of rheumatoid nodules.

Key words: rheumatoid arthritis, interleukin 1, prostaglandins.

Rheumatoid nodules occur in approximately 20% of patients with rheumatoid arthritis.1 These patients with rheumatoid arthritis tend to have high titres of rheumatoid factor. Histologically, a rheumatoid nodule is composed of three zones: an inner zone of central necrosis, a middle cellular palisading area, and an outer granulomatous area with perivascular infiltration of chronic inflammatory cells.1 2 The pathogenesis of rheumatoid nodules is not fully understood, though many factors, including proteolytic enzymes,3 trauma,4 immune complexes,5 and genetic factors,6 are believed to be involved.

Cytokines are indispensable for the physiological interaction of cells. Furthermore, abnormal production of these soluble factors may contribute to disordered immunoregulation in various autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis.7 Interleukin 1, especially, has multiple biological activities that include the induction of fever by acting on the hypothalamus, induction of the acute phase reactants from the liver, activation of polymorphonuclear cells, and stimulation of interleukin 2 production by T cells.8 Of particular relevance to rheumatoid arthritis, interleukin 1 induces the production of prostaglan-

dins and collagenase from synovial cells.9 Our examination of biopsied rheumatoid synovium indicated that interleukin 1 might be strongly involved in joint destruction in rheumatoid arthritis.10 We therefore studied the production of cytokines and prostaglandin E2 by rheumatoid nodules in an attempt to clarify the pathogenesis of these nodules.

Patients and methods

Nine patients (two men, seven women) with classical rheumatoid arthritis as defined by the American Rheumatism Association criteria11 were included in the study (Table 1). The duration of disease varied from eight months to 12 years, and nodules were present from two weeks to one year. All subjects except patient 7 were seropositive for rheumatoid factors, with titres ranging from 1/160 to 1/5120 on the haemagglutination test using sheep red blood cells sensitised with rabbit IgG (RAHA test). One patient was treated with 5 mg/day of prednisolone and one with 100 mg/day of β-penicillamine; the others received only non-steroidal anti-inflammatory drugs.

PREPARATION OF SAMPLES

Subcutaneous nodules were removed without complication from the olecranon region while patients were under local anaesthesia. The nodules were...
immediately cut into pieces 3 mm in diameter. Some of the samples were washed extensively with RPMI 1640 (Gibco, Grand Island, NY, USA) and plated into 24-well culture plates (Sumitomo, Japan) with RPMI 1640 supplemented with 10% fetal calf serum (Gibco), 100 units/ml penicillin, 100 µg/ml streptomycin, and 10 mM HEPES buffer (N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid; Sigma, St Louis, MO, USA). Culture supernatants were harvested at various intervals and assayed for interleukin 1, interleukin 2, and interleukin 3 activities, as described below. The rest of the samples were embedded in OCT medium (Miles, Naperville, IL, USA), frozen in liquid nitrogen, and stored at -70°C. In some experiments rheumatoid nodules were minced with scissors and plated into 24-well tissue culture plates in 10% fetal calf serum-RPMI 1640. When cell outgrowths were observed during the culture period the cells were collected and examined for cell surface antigens and responsiveness to various stimuli, including mitogens and interleukin 2, as described below.

**ASSAYS FOR CYTOKINE ACTIVITY**

Interleukin 1 activity was measured by a thymocyte proliferation assay. Briefly, 5×10⁵ thymocytes from C3H/HeJ mice (non-responders to lipopolysaccharide) were resuspended in RPMI 1640 with 10% fetal calf serum and plated in 96-well flat bottom tissue culture plates with a suboptimal dose of concanavalin A (Sigma, St Louis, MO, USA). Test samples or standard interleukin 1 (Genzyme, Boston, MA, USA) of various dilutions were added to the wells and incubated for 72 hours at 37°C in a 5% CO₂ incubator. Cell proliferation was measured by the incorporation of tritiated thymidine, as previously reported. One unit of interleukin 1 was defined as the reciprocal of the dilution at which 50% of the maximum response was obtained according to the method described by Matsuchima et al. Maximum response was obtained when 10 units/ml of standard interleukin 1 was used. To confirm interleukin 1 activity a growth inhibition assay using the melanoma cell line A375 was also employed. Briefly, A375 cells were plated into 96-well flat bottom culture plates (1×10⁶ cells/well) in Eagle’s minimum essential medium supplemented with 10% fetal calf serum with various dilutions of test samples or recombinant interleukin 1 (kindly provided by Dr Y Hirai of Otsuka Pharmaceutical Co Ltd). After four days' incubation at 37°C 0-5% neutral red was added to each well. Neutral red incorporated in viable cells was extracted with ethanol after two hours of culture. The optical density of each well was measured at 540 nm by a multiscan photometer. One unit per millilitre represented the reciprocal of the dilution of samples causing 50% cytostasis or cytolyis after four days of culture. Complete cytostasis was usually obtained when 125 ng/ml of recombinant interleukin 1β was used. In the experiments using the A375 cell line, samples with known interleukin 1-like activity were added to A375 cells with either polyclonal antihuman interleukin 1α antibody (OCT 303)(1:400 dilution), antihuman interleukin 1β antibody (OCT 204) (1:400), or an equivalent dose of normal rabbit IgG to determine whether these antibodies neutralised the interleukin 1-like activity in the samples. These antibodies, raised by immunising rabbits with either recombinant interleukin 1α or interleukin 1β, were kindly provided by Dr Y Hirai of Otsuka Pharmaceutical Co Ltd. The antibodies have been described in detail elsewhere. Interleukin 2 activity was assayed using an interleukin 2 dependent mouse cytotoxic T cell line, B6. Interleukin 3 activity was measured using an interleukin 3 dependent mouse cell line, IC2, kindly provided by Dr Y Koyasu. Purified interleukin 2 (Nihon Kohtai, Japan) and a culture supernatant of WEHI-3 were used as standards in interleukin 2 and interleukin 3 assays respectively. Both interleukin 2 and interleukin 3 activities were calculated according to the method described by Gillis et al.

**PROSTAGLANDIN E₂ ASSAY**

Prostaglandin E₂ in the culture media was measured by a radioimmunoassay kit (New England Nuclear, Boston, MA, USA) after extraction and silicic acid column chromatography, as described previously. Results were expressed as pg of prostaglandin E₂/ml (SEM).

**RESPONSE OF CELLS TO MITOGENS AND INTERLEUKIN 2**

Cell outgrowths from rheumatoid nodules were
collected and resuspended in RPMI 1640 containing 10% fetal calf serum. The cells were plated in 96-well tissue culture plates (1×10^5 cells/well) and cultured with an optimal dose of either phytohaemagglutinin (Difco, MI, USA), concanavalin A (Sigma), Staphylococcus aureus Cowan I (Calbiochem, La Jolla, CA, USA), or interleukin 2 for 72 hours. Thymidine incorporation was measured as described above.

**Immunohistochemical Staining**

Frozen tissues or cell smears were fixed with acetone and stained by monoclonal antibodies, as described below. Anti-CD2 (reactive with T11), anti-CD3 (reactive with T3), anti-CD4, anti-CD8, anti-CD20 and anti-CD21 (both reactive with B cells), anti-I2 (reactive with HLA-DR antigens), and anti-CD11b and anti-CD14 (both reactive with monocytes and myelocytes) were all products of Coulter Immunology (Hialeah, FL, USA) and the gift of Japan Scientific Instrument Company (Tokyo, Japan). Briefly, samples were incubated with a specific monoclonal antibody or a control antibody of the same isotype. The sections were rinsed and allowed to react with goat antimouse (IgG+IgM) antiserum, followed by mouse peroxidase-anti-peroxidase complex (Cappel, West Chester, PA), then the substrate, 3', 3'-diaminobenzidine.

**Detection of Rearrangement of T Cell Receptor β Gene**

High molecular weight DNA was extracted from frozen cell pellets containing approximately 2×10^7 cells outgrown from the rheumatoid nodules. The DNA samples were digested with the restriction enzymes EcoRI or Hind III (Takarashuzo, Japan) and subjected to electrophoresis on 0-8% agarose gels. After denaturation and neutralisation the DNA was transferred to nitrocellulose paper by the technique of Southern. Hybridisation to a randomly primed 32P labelled DNA probe of the constant region of the T cell receptor gene was performed, followed by washing at the appropriate stringency, then autoradiography. Non-lymphoid control DNA was run simultaneously in order to identify the germ-line position of the gene examined.

**Statistical Analysis**

Statistical analysis was by Student’s t test.

**Results**

**Interleukin 1-like Activity in Supernatants from Cultured Rheumatoid Nodule Tissue**

When supernatants from cultured rheumatoid nodules were all products of Coulter Immunology (Hialeah, FL, USA) and the gift of Japan Scientific Instrument Company (Tokyo, Japan). Each sample was tested in duplicate, with an average of 3, 3'-diaminobenzidine.

<table>
<thead>
<tr>
<th>Interleukin 1</th>
<th>Interleukin 2</th>
<th>Interleukin 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid nodules</td>
<td>(n=9)</td>
<td>5.0 (1-2)</td>
</tr>
</tbody>
</table>

**Table 2. Activities of interleukin 1, interleukin 2, and interleukin 3 detected in the culture supernatants 24 hours after initiation of the culture from rheumatoid nodules. Values are mean (SE).**

**Fig. 1** Interleukin 1-like activity in the supernatant from a cultured rheumatoid nodule one to seven days after the initiation of culture. The results of a representative experiment are shown. IL-1=interleukin 1.

**Fig. 2** The effect of anti-interleukin 1α or anti-interleukin 1β antibody on interleukin 1-like activity in a supernatant from a cultured rheumatoid nodule. Results from a representative experiment are shown. IL-1=interleukin 1.
nodule tissue were added to concanavalin A stimulated thymocyte cultures at dilutions of 1:1 to 1:4 there was a significant reduction in thymidine incorporation compared with cultures that had higher dilutions (1:8 or higher) of the same supernatants (data not shown). This suggested that inhibitory factor(s), including prostaglandins, might be contained in the supernatants from cultured rheumatoid nodule tissue. We therefore used supernatants with dilutions higher than 1:8 to test for interleukin 1-like activity.

Supernatants from cultured rheumatoid nodule tissue harvested on day 1 of culture induced significant proliferation of thymocytes stimulated with a suboptimal dose of concanavalin A (5.0 (1.2) U/ml, mean (SE)) (Table 2). This activity was greater on day 1 of culture than on days 4 or 7 (Fig. 1). In addition, there was a tendency for this activity to be more pronounced in 'fresh' nodules—that is, 6.4 (1.0) U/ml from fresh nodules (duration <8 weeks) vs 4.0 (1.0) U/ml from 'old' nodules (duration >3 months) (p<0.01). Interleukin 1 activity was confirmed by growth inhibition assay using the melanoma cell line A375. Thus supernatants from day 1 of culture of rheumatoid nodule tissue significantly inhibited proliferation of the melanoma cell line (13.8 (2.5) U/ml, mean (SE)). Furthermore, the interleukin 1-like activity in the supernatants was not blocked by anti-interleukin 1α antibody. It was significantly inhibited by anti-interleukin 1β antibody (up to 75%), but not by normal rabbit IgG, indicating that most of the interleukin 1-like activity could be ascribed to the interleukin 1β molecule (Fig. 2). By contrast, neither interleukin 2 nor interleukin 3 activity was detected in the supernatants from any of the culture samples tested.

**Prostaglandin E2 in Supernatants from Cultured Rheumatoid Nodule Tissue**

Supernatants from cultured rheumatoid nodule tissue contained considerable amounts of prostaglandin E2 (3650 (SE 1524) pg/ml), suggesting that prostaglandin E2 is spontaneously produced in rheumatoid nodules. There was no correlation between the amount of prostaglandin E2 in the supernatants and interleukin 1 activity, and duration of rheumatoid nodules.

**Surface Antigens of Cells Outgrown from Rheumatoid Nodules**

When fresh rheumatoid nodules were minced and pieces of these tissues were cultured, round mononuclear cells appeared around the tissues forming colonies (Fig. 3). These cells were relatively large in size and had small round nuclei with large cytoplasms.

We therefore examined their surface antigens using indirect immunostaining. Results showed that these cells strongly expressed HLA-DR antigens.

Fig. 3 A colony forming around tissue biopsied from a rheumatoid nodule.
both in their cytoplasms and on their surfaces (Fig. 4). They also bore CD14 antigens on their surfaces. None of the T cell or B cell differentiation antigens so far tested was demonstrated, however. CD11b (Mo1) antigens were weakly detected. These results suggest that these cells may belong to the macrophage lineage (Table 3).

Table 3  Surface antigens of cells outgrown from rheumatoid nodules

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-DR</td>
<td>+</td>
</tr>
<tr>
<td>CD4</td>
<td>-</td>
</tr>
<tr>
<td>CD14</td>
<td>+</td>
</tr>
<tr>
<td>CD8</td>
<td>-</td>
</tr>
<tr>
<td>CD11b</td>
<td>+</td>
</tr>
<tr>
<td>CD20</td>
<td>-</td>
</tr>
<tr>
<td>CD3</td>
<td>-</td>
</tr>
</tbody>
</table>

Cells were stained by various monoclonal antibodies as described in the 'Patients and methods' section.

RESPONSIVENESS OF CELLS OUTGROWN FROM RHEUMATOID NODULES IN VITRO

We next studied the responsiveness of these cells to various stimuli in a proliferation assay. These cells did not synthesise DNA in vitro by responding to any of the stimuli tested: phytohaemagglutinin, concanavalin A, S aureus Cowan I, and interleukin 2 (data not shown). Further, they did not spontaneously incorporate tritiated thymidine. These data indicate that these cells may not be lymphocytic in origin.

PRODUCTION OF INTERLEUKIN 1-LIKE FACTOR BY CELLS IN VITRO

When these cells were collected and cultured in vitro $(5 \times 10^5 \text{ cells/well})$ they spontaneously elaborated an interleukin 1-like factor. Thus supernatants from these cultured cells supported a proliferation of concanavalin A stimulated thymocytes $(5.0 (1.2) \text{ U/ml})$ and inhibited growth of the A375 melanoma cell line $(10.0 (2.6) \text{ U/ml})$. This activity peaked on day 1 of culture and gradually declined on subsequent days. This interleukin 1-like activity was also neutralised by anti-interleukin 1\(\beta\) antibody (data not shown). No other cytokine activity, including that of interleukin 2 and interleukin 3, was detected in these supernatants.

REARRANGEMENT OF T CELL RECEPTOR \(\beta\) CHAIN GENE

DNA from circulating granulocytes was used as non-T cells to define the normal germ-line arrangement of the T cell receptor \(\beta\) chain gene. When DNA from cells outgrown from a rheumatoid nodule was studied it manifested T cell \(\beta\) genes in the germ-line configuration. No rearranged band was observed (data not shown). These data suggested that the cells obtained from rheumatoid nodules were not of T cell origin.

Discussion

Subcutaneous rheumatoid nodules are one of the extra-articular symptoms seen in rheumatoid arthritis. They are frequently found on pressure points.

Fig. 4  Immunohistochemical analysis of cells outgrown from a rheumatoid nodule. (a) Staining with irrelevant mouse IgG; (b) staining with anti-HLA-DR antibody. Most of the cells are strongly reactive with anti-HLA-DR antibody.
bony prominences and are associated with seropositivity in patients with rheumatoid arthritis. The pathogenesis of rheumatoid nodules remains to be elucidated, however.

We found both interleukin 1 like activity and prostaglandin E2 in supernatants from cultured rheumatoid nodule tissue. Interleukin 1 like activity was confirmed by both thymocyte proliferation assay and growth inhibition assay using a melanoma cell line. This activity was significantly inhibited by antihuman interleukin 1 antibodies, especially by the antibody to recombinant interleukin 1β. Cells producing interleukin 1 activity in the nodules seem to be monocytic in origin. They responded neither to T cell nor to B cell mitogens and expressed CD14 and HLA-DR antigens on their surfaces. In addition, these cells showed the germ-line configuration of a T cell receptor gene, indicating that they are not of T cell origin. These cells have a phagocytic function (data not shown). Hedfors et al., using an immunohistochemical technique, showed that cells within the palisading layer were phenotypically 'macrophage-like'. Other investigators have also reported that rheumatoid nodules are composed largely of HLA-DR+ macrophages.22 Furthermore, Palmer et al recently showed that the great majority of palisade cells in rheumatoid nodules express exclusively mononuclear phagocyte phenotypes.23 Our present study confirmed their results. We are currently examining the functions of these cells—for example, their ability to present antigens to T cells. It is possible that interleukin 1 produced locally by these cells induces the proliferation of fibroblasts,24 which in turn promotes palisade formation in the middle layer of rheumatoid nodules. The signal(s) for interleukin 1 production by these cells are not known at present, but they could be sent out by T cells infiltrating the outer layer of rheumatoid nodules. Interleukin 1 could also stimulate synovial cells or fibroblasts to produce collagenase and prostaglandin E2,9 possibly causing central necrosis in the inner layer of rheumatoid nodules, as Harris speculated.3

Using both organ culture7 and cloned synovial cells,25 we have shown that interleukin 1 like factor is produced in rheumatoid synovium. Collectively, three morphologically different cells were cloned from rheumatoid synovium—dendritic cells, macrophage-like cells, and fibroblast-like cells—all of which spontaneously elaborated interleukin 1 like factor(s) in culture. Furthermore, a significant amount of this activity was detected in the supernatants of cultures of biopsied rheumatoid synovium. The activity correlated well with the vascularity of the tissue as shown by arthroscopy, bony destruction as observed by x ray films, and the expression of HLA-DR antigen on proliferating synovial cells.7 In addition, one of our collaborators recently found that cloned rheumatoid synovial cells, especially macrophage-like cells and dendritic cells, spontaneously produced prostaglandin E2 in culture (Sasano, Goto, Nishioka, unpublished data). This, together with our present data, indicates that interleukin 1 and prostaglandin E2 may be strongly involved in both the pathogenesis of synovitis and the formation of rheumatoid nodules in rheumatoid arthritis.

This study is the first to look at the production of cytokines by rheumatoid nodules in an attempt to shed light on their pathogenesis. We are currently studying the cascades or networks of cytokine production in both rheumatoid nodules and rheumatoid synovium.

We are grateful to Japan Scientific Instrument Company for providing monoclonal antibodies, to Ms Junko Hirose and Ms Hiroko Inoue for their technical assistance, and Ms Hiromi Kishi for her superb secretarial work. This work was partly supported by a grant-in-aid from the Ministry of Health and Welfare, Japan.

References
13 Matsushima K, Procopio A, Abe H, Scala G, Ortaldo J, Oppenheim J. Production of interleukin-1 activity by normal